Report Highlights

China Propolis Market: Market Overview

China's propolis market is structured across three distinct commercial layers: raw hive-sourced propolis harvested domestically, standardised flavonoid-rich extracts processed for supplement and pharmaceutical use, and finished consumer products sold through pharmacy chains, health food retailers, and rapidly expanding e-commerce platforms. The market generated USD 312.4 million in 2024 and is forecast to reach USD 587.8 million by 2032. Government policy has been the dominant force in shaping how propolis is classified, labelled, and sold — specifically through the National Medical Products Administration's categorisation of propolis products as either health foods, cosmetics, or general food, each carrying separate approval requirements and compliance costs that fundamentally determine commercial viability.

Private sector innovation has led product development, particularly among domestic brands such as Zhejiang Bee Products and BY-HEALTH, which have invested in standardised extraction technology to meet the NMPA's requirement for declared active ingredient concentrations. However, the regulatory framework has constrained market entry, with health food registration under the Food Safety Law taking 24–36 months and costing RMB 500,000–1,200,000 per product SKU. This has concentrated market share among established players with regulatory capital, while smaller beekeeping cooperatives remain largely confined to raw material supply roles, unable to access the higher-margin finished product segment without significant compliance investment.

Policy-Driven Growth in Propolis in China

Three specific policy mechanisms are actively driving demand growth in the Chinese propolis market. First, the Healthy China 2030 Action Plan, issued by the State Council in 2019, established national targets for expanding preventive healthcare consumption, explicitly listing bee products as a recognised category within traditional Chinese medicine-aligned functional foods. This has enabled propolis supplement manufacturers to access the National Development and Reform Commission's funding streams under the 14th Five-Year Plan for the health industry, unlocking subsidised production capacity upgrades worth approximately RMB 2.1 billion industry-wide between 2021 and 2025. The mechanism is direct: government endorsement reduces consumer scepticism and grants marketing legitimacy that private advertising alone cannot achieve.

Second, the NMPA's Registered Health Food catalogue — governed by the Measures for the Administration of Health Food Registration and Filing (2016, amended 2020) — formally lists propolis flavonoids as a permitted functional ingredient for immunity-support claims, giving registered products access to pharmacy retail channels closed to unregistered competitors. Third, China's Rural Revitalisation Strategy, administered by the Ministry of Agriculture and Rural Affairs, includes targeted beekeeping development subsidies under the 2021 National Beekeeping Industry Development Plan, providing direct payments of RMB 200–500 per hive per year to qualifying apiaries. This policy has expanded the domestic propolis supply base, reducing raw material costs by an estimated 12–15% between 2021 and 2024 and improving processor margins sufficiently to fund downstream product development.

Regulatory Barriers and Compliance Costs

The most substantial regulatory barrier is the dual-track registration system administered by the NMPA, which requires propolis products making functional health claims to obtain Blue Hat certification under the Food Safety Law of China (2015) and its implementing regulations. The process involves clinical substantiation, production site GMP inspection by NMPA-appointed third-party auditors, and labelling review — consuming an average of 28 months and RMB 800,000–1,200,000 per registered product. Foreign brands importing propolis products face additional barriers: all overseas manufacturers must achieve GACC registration for food-grade facilities under the General Administration of Customs Announcement No. 248 (2021), which requires on-site inspection by Chinese customs officials — a process that has taken 18–30 months for facilities in Brazil and New Zealand due to bilateral inspection scheduling constraints.

Local content requirements do not apply directly to propolis, but NMPA's 2022 Special Food Safety Supervision Guidance requires that any health food containing imported propolis above 30% of formulation weight must disclose the country of origin on the primary label — a rule that disadvantages Brazilian propolis blends against domestic equivalents in pharmacy channels where Chinese-origin labelling carries a perceived quality signal for traditional medicine products. Price controls are not formally applied to propolis, but the National Healthcare Security Administration's periodic review of supplement reimbursement lists indirectly suppresses wholesale pricing in hospital-linked channels where propolis tinctures are sold as adjunct treatments. Combined compliance costs for a mid-sized entrant seeking Blue Hat certification for three SKUs typically exceed RMB 3.5 million before first commercial sale.

Policy-Created Opportunities in China

The NMPA's 2023 pilot reform programme for Health Food Filing — as distinct from full registration — creates a direct commercial opportunity for propolis products that use only pre-approved ingredients at pre-approved dosages listed in the NMPA's permitted ingredient catalogue. Under this filing pathway, time-to-market compresses from 28 months to approximately 6–9 months, and costs fall to RMB 150,000–300,000 per SKU. Propolis flavonoid extract at concentrations between 10mg and 50mg per daily serving qualifies under the current catalogue parameters. This opens a viable market entry route for smaller domestic brands and foreign players willing to standardise their formulations to catalogue specifications — a strategic concession that the NMPA has deliberately designed to stimulate category competition and consumer price relief.

A second opportunity arises from the Ministry of Commerce's Cross-Border E-Commerce (CBEC) Positive List, which includes propolis extracts and standardised supplements under HS Code 2106.90, permitting direct-to-consumer import sales through bonded warehouse platforms such as Tmall Global and JD Worldwide without requiring full NMPA health food registration for individual products below specified import thresholds. This CBEC channel generated an estimated RMB 1.4 billion in propolis-related sales in 2024, growing at 19% annually — nearly double the rate of the domestic registered product segment. Brands that position via CBEC can build consumer recognition and sales volume before committing to the capital-intensive Blue Hat registration process, effectively using the channel as a commercially funded regulatory staging period.

Market at a Glance

Leading Market Participants

• Zhejiang Bee Products Co., Ltd.
• BY-HEALTH Co., Ltd.
• Comvita Limited
• ApiHealth NZ Ltd.
• Swisse Wellness
• Shanghai Greenspring Biological Technology
• Beekeeper's Naturals
• Dalian Bees Health Technology
• Wuhan Beegreen Biological Product
• Naturex (Givaudan Group)

Regulatory and Policy Environment

The primary legislative framework governing propolis in China is the Food Safety Law of the People's Republic of China (2015, amended 2021), implemented through the Measures for the Administration of Health Food Registration and Filing (NMPA Order No. 1, 2016, amended 2020) and the Cosmetic Supervision and Administration Regulation (State Council Decree No. 727, 2020) for topical propolis applications. The NMPA's Food Review Centre (CFRC) is the designated approval authority for health food registration, while provincial Market Supervision and Administration Bureaus handle post-market inspection. Key compliance requirements include GMP certification under GB 17405-2016, declaration of total flavonoid content per serving unit, and mandatory adverse event reporting within 15 working days. An upcoming revision to the permitted health claims catalogue, expected in Q3 2025, will add anti-oxidation and gut microbiota support as declarable functions — directly expanding the commercial positioning options for standardised propolis extracts without requiring new clinical substantiation for brands already registered under existing immunity-support claims.

Compared to regional peers, China's propolis regulatory framework is the most structurally rigorous in Asia-Pacific. Japan classifies propolis as a general food ingredient with voluntary quality standards administered by the Japan Propolis Conference, requiring no pre-market approval. South Korea permits propolis under the Health Functional Food Act with a 90-day notification pathway — approximately one-tenth the time required in China. Australia's TGA classifies propolis as a listed complementary medicine with self-certification, whereas China requires third-party clinical dossier review. This regulatory asymmetry means that brands successfully navigating China's framework carry a de facto quality signal recognised in export markets and by Chinese consumers, but the compliance burden is a genuine structural cost that shapes which competitors can participate at scale in the registered product segment.

Long-Term Policy Outlook for China Propolis

By 2032, two regulatory developments are likely to materially reshape the propolis market. The NMPA is expected to complete its transition to a fully digital health food registration platform — announced under the 2023 Smart Regulation Initiative — which will standardise dossier submission, reduce manual review time, and create a public database of registered products accessible to retail buyers and e-commerce platforms. This transparency will intensify price competition among Blue Hat registered products, compressing margins for brands whose positioning relies primarily on regulatory status rather than demonstrable clinical differentiation. Simultaneously, the Ministry of Agriculture and Rural Affairs is expected to publish mandatory quality standards for raw propolis under a proposed national standard (GB/T revision of the current voluntary GB/T 24283-2009), which will require minimum flavonoid concentrations and heavy metal limits at the raw material stage — raising the floor quality of domestically produced propolis and eliminating low-grade supply that currently depresses average market pricing.

The long-term policy trajectory also includes expanding the CBEC positive list scope and raising per-consumer import thresholds, which the Ministry of Commerce has signalled as a priority under the 2024 Action Plan for High-Quality Development of Cross-Border E-Commerce. If implemented as proposed, annual per-consumer CBEC purchase limits for health supplements — currently set at RMB 26,000 — will rise to RMB 36,000 by 2027, directly expanding addressable demand for premium imported propolis products from New Zealand and Brazil. Combined with the NMPA's filing pathway reforms, these changes will create a bifurcated market by 2032: a regulated domestic segment competing on clinical validation and a CBEC-driven premium import segment competing on provenance and brand, with limited overlap between consumer groups and pricing tiers.

Market Segmentation

By Product Type

• Raw Propolis
• Propolis Extract (Liquid)
• Propolis Extract (Powder)
• Propolis Capsules and Tablets
• Propolis Cosmetics
• Propolis Functional Food

By Application

• Dietary Supplements
• Skincare and Cosmetics
• Pharmaceutical Intermediates
• Oral Care Products
• Food and Beverage Fortification

By Distribution Channel

• E-Commerce (Domestic Platforms)
• Cross-Border E-Commerce (CBEC)
• Pharmacy Chains
• Health Food Specialty Stores
• Direct Sales and MLM
• Hospital and Clinical Channels

By Origin

• Domestic Chinese Propolis
• Brazilian Green Propolis (Imported)
• New Zealand Propolis (Imported)
• European Poplar Propolis (Imported)

Frequently Asked Questions

Q1. What is the Blue Hat certification and why is it mandatory for propolis supplements sold in China? ▼

Blue Hat certification is the NMPA's official approval mark for health foods under the Food Safety Law (2015), required for any propolis product making functional health claims such as immunity support. Without it, products cannot be labelled as health foods, cannot be sold in pharmacy health food sections, and are prohibited from making efficacy statements in advertising.

Q2. How does GACC Announcement No. 248 (2021) affect foreign propolis suppliers entering China? ▼

Announcement No. 248 requires all overseas food manufacturers — including propolis processors in Brazil, New Zealand, and Australia — to register their production facilities with the General Administration of Customs before exporting to China. Unregistered facilities have their shipments refused at Chinese ports of entry, regardless of product quality or existing commercial relationships with Chinese importers.

Q3. Can propolis products be sold in China through cross-border e-commerce without NMPA health food registration? ▼

Yes, propolis extracts and supplements listed under HS Code 2106.90 on the CBEC Positive List can be sold directly to Chinese consumers via bonded warehouse platforms such as Tmall Global without individual NMPA health food registration. However, per-transaction and annual per-consumer import value limits apply, and health claim advertising remains restricted under NMPA advertising regulations even in CBEC channels.

Q4. What upcoming regulatory change will most affect propolis market participants before 2027? ▼

The anticipated revision to the NMPA's declarable health function catalogue, expected in Q3 2025, will add anti-oxidation and gut microbiota support as permitted claims for registered propolis products — broadening commercial positioning without requiring new clinical trials for existing Blue Hat registrants. Simultaneously, the proposed mandatory GB/T raw propolis quality standard will raise minimum flavonoid content thresholds, forcing lower-grade domestic producers to upgrade processing or exit the supply chain.

Q5. How does China's propolis regulatory framework compare to South Korea and Japan for market entry planning? ▼

China requires 24–36 months and up to RMB 1.2 million per SKU for health food registration, versus a 90-day notification pathway in South Korea and no pre-market approval in Japan for propolis as a general food ingredient. Brands expanding across Asia-Pacific typically use Japan and South Korea as first-entry markets to build sales history and brand recognition before committing to China's registration investment.